VaxGen Concludes Early Stage Meningitis B Vaccine Collaboration with EndoBiologics

01-Jun-2006

VaxGen, Inc. announced that it is ending a collaboration with EndoBiologics International Corp. VaxGen announced in May 2005 that it would fund proof-of-concept studies and then determine whether to pursue commercial development of the vaccine candidate. The initial proof-of-concept phase was undertaken jointly by EndoBiologics and VaxGen, with VaxGen providing research funding to EndoBiologics and conducting pre-clinical testing of the vaccine candidate.

"Although we do not wish to pursue commercial development of this product, we will continue to look for other opportunities to develop a vaccine candidate against Meningitis B," said Lance K. Gordon, Ph.D., VaxGen's President and Chief Executive Officer.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances